SCHEMBL23675360

SCHEMBL23675360

O=C(Nc1cc(F)cc(C(F)(F)F)c1)c1ccc(Cl)cc1O

nearest known ligand 0.85

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
P2RX1 P51575 14/20 0.85
TMPRSS4 Q9NRS4 11/20 0.85
P2RX7 Q99572 9/20 0.85
P2RX4 Q99571 8/20 0.85
MEN1 O00255 1/20 0.68
IKBKB O14920 1/20 0.68
CHUK O15111 1/20 0.68
KDR P35968 1/20 0.68
FLT3 P36888 1/20 0.68
KMT2A Q03164 1/20 0.68
MYLK Q15746 1/20 0.68
MAP4K5 Q9Y4K4 1/20 0.68
SLC2A1 P11166 1/20 0.57
XPO1 O14980 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30100397 1.00 P2RX1 (0.85) P2RX1TMPRSS4P2RX7P2RX4MEN1
SCHEMBL130143 0.92 P2RX1 (1.00) P2RX1TMPRSS4P2RX7P2RX4MEN1
SCHEMBL30100386 0.90 TMPRSS4 (0.85) P2RX1TMPRSS4P2RX7P2RX4MEN1
SCHEMBL131758 0.90 TMPRSS4 (0.85) P2RX1TMPRSS4P2RX7P2RX4MEN1
SCHEMBL30100462 0.90 TMPRSS4 (0.85) P2RX1TMPRSS4P2RX7P2RX4MEN1
SCHEMBL25349155 0.84 TMPRSS4 (0.80) P2RX1TMPRSS4P2RX7P2RX4MEN1
SCHEMBL23675377 0.83 P2RX1 (0.84) P2RX1TMPRSS4P2RX7P2RX4MEN1
SCHEMBL23303570 0.82 P2RX1 (0.60) P2RX1TMPRSS4P2RX7P2RX4MEN1
Imd-0354 SCHEMBL129165 0.81 TMPRSS4 (1.00) P2RX1TMPRSS4P2RX7P2RX4MEN1
SCHEMBL13812702 0.81 TMPRSS4 (0.94) P2RX1TMPRSS4P2RX7P2RX4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) 2023-05-04 US claimed
WO-2021151104-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-07-29 WO claimed
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING THE BOARD OF REGENTS OF THE UNIV OF TEXAS SY (US) 2023-05-04 US disclosed
EP-4093401-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING The Board of Regents of the University of Texas System (US) 2022-11-30 EP disclosed
WO-2021151104-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140290-A1 SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING EIF2AK2, SARS1, ACE P2RX1 3088/4885TMPRSS4 526/4885P2RX7 3141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.